To our knowledge, no previous studies in patients with BE or any other human premalignant condition have prospectively evaluated the contributions of TP53 and CDKN2A gene inactivation (methylation, mutation, and LOH) and DNA content abnormalities in combination with candidate interventions to assess their potential utility as biomarkers for future cancer risk and cancer prevention. The gene discussed is TP53; the disease is cancer.